Dr. Reddy's Q1 miss extends pattern from prior quarter

 

Q1 FY27 earnings miss with 69% profit plunge sinks RDY 5.97%

• Net profit ~₹444 Cr, down 69% YoY and below estimates
• Revenue fell ~6% YoY to ₹8,071 Cr on weak North America sales
• North America generics revenue dropped 35% due to lower lenalidomide sales
• EBITDA margin compressed sharply to 12.5% from 26.7% prior year
• ₹240 Cr provision for semaglutide API issues reduced margins ~3%
• Results released July 22 with 10AM ET earnings call
• Extends pattern from prior quarter's earnings miss

https://finviz.com/stock?t=RDY&p=d